358 related articles for article (PubMed ID: 25034573)
21. Feasibility and efficacy of gonadotropin-releasing hormone agonists for the prevention of chemotherapy-induced ovarian insufficiency in patients with malignant ovarian germ cell tumours (KGOG 3048R).
Choi MC; Chung YS; Lee JW; Kwon BS; Park BK; Kim SI; Shim SH; Lee KB; Seong SJ; Lee SJ; Lee SH; Yoo HJ; Song T; Kim MK; Baek MH; Kang S; Kim YM
Eur J Cancer; 2020 Jul; 133():56-65. PubMed ID: 32442924
[TBL] [Abstract][Full Text] [Related]
22. Anti-müllerian hormone as a marker of ovarian function in women after chemotherapy and radiotherapy for haematological malignancies.
Lie Fong S; Lugtenburg PJ; Schipper I; Themmen AP; de Jong FH; Sonneveld P; Laven JS
Hum Reprod; 2008 Mar; 23(3):674-8. PubMed ID: 18216040
[TBL] [Abstract][Full Text] [Related]
23. Survival and reproductive function after treatment of malignant germ cell ovarian tumors.
Zanetta G; Bonazzi C; Cantù M; Binidagger S; Locatelli A; Bratina G; Mangioni C
J Clin Oncol; 2001 Feb; 19(4):1015-20. PubMed ID: 11181664
[TBL] [Abstract][Full Text] [Related]
24. Comparison of antimüllerian hormone levels and antral follicle count as predictor of ovarian response to controlled ovarian stimulation in good-prognosis patients at individual fertility clinics in two multicenter trials.
Nelson SM; Klein BM; Arce JC
Fertil Steril; 2015 Apr; 103(4):923-930.e1. PubMed ID: 25624196
[TBL] [Abstract][Full Text] [Related]
25. Malignant ovarian germ cell tumors: a single-institution experience.
Cicin I; Eralp Y; Saip P; Ayan I; Kebudi R; Iyibozkurt C; Tuzlali S; Gorgun O; Topuz E
Am J Clin Oncol; 2009 Apr; 32(2):191-6. PubMed ID: 19307952
[TBL] [Abstract][Full Text] [Related]
26. Antimüllerian hormone in gonadotropin releasing-hormone antagonist cycles: prediction of ovarian response and cumulative treatment outcome in good-prognosis patients.
Arce JC; La Marca A; Mirner Klein B; Nyboe Andersen A; Fleming R
Fertil Steril; 2013 May; 99(6):1644-53. PubMed ID: 23394782
[TBL] [Abstract][Full Text] [Related]
27. Fertility-sparing surgery in advanced stage malignant ovarian germ cell tumor: a case report.
Ghalleb M; Bouzaiene H; Slim S; Hadiji A; Hechiche M; Ben Hassouna J; Rahal K
J Med Case Rep; 2017 Dec; 11(1):350. PubMed ID: 29248013
[TBL] [Abstract][Full Text] [Related]
28. Reproductive function after treatment of ovarian germ cell malignancy.
Anita AN; Rushdan MN
Med J Malaysia; 2012 Feb; 67(1):71-6. PubMed ID: 22582552
[TBL] [Abstract][Full Text] [Related]
29. [Systematic proposal of fertility preservation by mature oocyte cryopreservation for recurrent benign ovarian tumors].
Dadoun Y; Azaïs H; Keller L; d'Orazio E; Collinet P; Decanter C
Gynecol Obstet Fertil Senol; 2017 Jun; 45(6):359-365. PubMed ID: 28506797
[TBL] [Abstract][Full Text] [Related]
30. Assessment of ovarian reserve in adult childhood cancer survivors using anti-Müllerian hormone.
Lie Fong S; Laven JS; Hakvoort-Cammel FG; Schipper I; Visser JA; Themmen AP; de Jong FH; van den Heuvel-Eibrink MM
Hum Reprod; 2009 Apr; 24(4):982-90. PubMed ID: 19153092
[TBL] [Abstract][Full Text] [Related]
31. Follicular fluid anti-Müllerian hormone and inhibin B concentrations: comparison between gonadotropin-releasing hormone (GnRH) agonist and GnRH antagonist cycles.
Lee JR; Kim SH; Kim SM; Jee BC; Ku SY; Suh CS; Choi YM; Kim JG; Moon SY
Fertil Steril; 2008 Apr; 89(4):860-7. PubMed ID: 18249372
[TBL] [Abstract][Full Text] [Related]
32. Anti-Mullerian hormone: determination of ovarian reserve in early breast cancer patients.
Bozza C; Puglisi F; Lambertini M; Osa EO; Manno M; Del Mastro L
Endocr Relat Cancer; 2014 Feb; 21(1):R51-65. PubMed ID: 24292601
[TBL] [Abstract][Full Text] [Related]
33. [Adjuvant therapy of malignant ovarian tumors after organ preserving surgery].
Schröder W
Zentralbl Gynakol; 1996; 118(10):565-70. PubMed ID: 8912476
[TBL] [Abstract][Full Text] [Related]
34. Malignant ovarian germ cell tumor in King Chulalongkorn Memorial Hospital.
Lertkhachonsuk R; Termrungruanglert W; Vasuratna A; Sittisomwong T; Worasethsin P; Tresukosol D
J Med Assoc Thai; 2005 Sep; 88 Suppl 4():S124-8. PubMed ID: 16623016
[TBL] [Abstract][Full Text] [Related]
35. Clinical management of malignant ovarian germ cell tumors: A 26-year experience in a tertiary care institution.
Hu T; Fang Y; Sun Q; Zhao H; Ma D; Zhu T; Wang C
Surg Oncol; 2019 Dec; 31():8-13. PubMed ID: 31446304
[TBL] [Abstract][Full Text] [Related]
36. Oocyte cryopreservation for fertility preservation in postpubertal female children at risk for premature ovarian failure due to accelerated follicle loss in Turner syndrome or cancer treatments.
Oktay K; Bedoschi G
J Pediatr Adolesc Gynecol; 2014 Dec; 27(6):342-6. PubMed ID: 25214440
[TBL] [Abstract][Full Text] [Related]
37. The role of anti-Müllerian hormone in female fertility and infertility - an overview.
Grynnerup AG; Lindhard A; Sørensen S
Acta Obstet Gynecol Scand; 2012 Nov; 91(11):1252-60. PubMed ID: 22646322
[TBL] [Abstract][Full Text] [Related]
38. Female patients with lymphoma demonstrate diminished ovarian reserve even before initiation of chemotherapy when compared with healthy controls and patients with other malignancies.
Lekovich J; Lobel ALS; Stewart JD; Pereira N; Kligman I; Rosenwaks Z
J Assist Reprod Genet; 2016 May; 33(5):657-662. PubMed ID: 26943918
[TBL] [Abstract][Full Text] [Related]
39. [Multicenter randomized controlled clinical study for the operative treatment of malignant ovarian germ cell tumors].
Liu Q; Ding XL; Yang JX; Cao DY; Shen K; Lang JH; Zhang GN; Xin XY; Xie X; Zhang SL; Wu YM; Zhu GH; Wang J; Chen YL; Kong BH; Zheng JH
Zhonghua Fu Chan Ke Za Zhi; 2013 Mar; 48(3):188-92. PubMed ID: 23849941
[TBL] [Abstract][Full Text] [Related]
40. The dynamics of serum anti-Mullerian-hormone levels during controlled ovarian hyperstimulation with GnRH-antagonist short protocol in polycystic ovary syndrome and low responders.
Weintraub A; Margalioth EJ; Chetrit AB; Gal M; Goldberg D; Alerhand S; Eldar-Geva T
Eur J Obstet Gynecol Reprod Biol; 2014 May; 176():163-7. PubMed ID: 24630573
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
